featured
Nivolumab vs Nivolumab Plus Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A randomized comparison of nivolumab versus nivolumab + docetaxel for previously treated advanced or recurrent ICI-naïve non-small-cell lung cancer: TORG1630
Clin. Cancer Res 2022 Aug 18;[EPub Ahead of Print], Y Taniguchi, T Shimokawa, Y Takiguchi, T Misumi, Y Nakamura, Y Kawashima, N Furuya, Y Shiraishi, T Harada, H Tanaka, S Miura, A Uchiyama, Y Nakahara, T Tokito, K Naoki, A Bessho, Y Goto, M Seike, H OkamotoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.